A Novartis team couriers an experimental treatment across Europe to a patient as transit grinds to a halt.

A complex protein module keeps the liver’s biochemical factory running smoothly and at capacity.

Novartis investigators find genetic explanations for why some young patients relapse.

Van der Kamp explains how leading by example has encouraged others to adopt flexible working models.

Low- and middle-income countries will account for some three in four of the world’s cancer deaths within the next decade without better access to care. It’s a gap Amy Israel and her team at Novartis are trying to bridge.